Cancer Treatment Reviews

Article	Citations
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis	221
MYC as a target for cancer treatment	220
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies	140
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality	127
Global challenges and policy solutions in breast cancer control	117
Microsatellite instability in Gastric Cancer: Between lights and shadows	112
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy	110
Targeting FGFR inhibition in cholangiocarcinoma	109
Treatment landscape of metastatic pancreatic cancer	107
BAP1: Not just a BRCA1-associated protein	105
MEK inhibitor resistance mechanisms and recent developments in combination trials	101
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives	90
Targeting ARID1A mutations in cancer	86
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins	83
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management	82
NRAS mutant melanoma: Towards better therapies	75
Immunotherapy in non-small cell lung cancer harbouring driver mutations	66
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges	64
Roadmap to cure multiple myeloma	60
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis	60
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	58
Treatment strategies for patients with diffuse large B-cell lymphoma	56
Targeting brain metastases in breast cancer	55
Targeting HER2 heterogeneity in breast cancer	54
Turning tumors from cold to inflamed to improve immunotherapy response	53

Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis	51
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis	48
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis	47
Liquid biopsy in lymphoma: Molecular methods and clinical applications	47
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials	47
Cabozantinib: An evolving therapy for hepatocellular carcinoma	47
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives	46
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond	45
A basic review on systemic treatment options in WHO grade II-III gliomas	45
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis	44
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer	44
Neurological complications of cancer immunotherapy	42
Precision medicine in breast cancer: From clinical trials to clinical practice	41
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification	41
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer	39
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone	39
SELNET clinical practice guidelines for soft tissue sarcoma and GIST	39
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives	37
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials	37
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis	37
Immunotherapy in cervix cancer	36
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer	36
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities	36
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?	35
The current clinical landscape of personalized cancer vaccines	35
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus	35
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice	35
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials	34
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges	34
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities	34
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines	33
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	33
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)	33
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era	31
Accelerating drug development in breast cancer: New frontiers for ER inhibition	31
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future	31
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer	30
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?	30
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors	30
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer	29
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer	29
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care	29
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours	28
The promise of bispecific antibodies: Clinical applications and challenges	28
Recent advancements of antiangiogenic combination therapies in ovarian cancer	28
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis	27
Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review	27
Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review	27
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations	27
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer	27

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immorta	27
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review	27
Newly diagnosed ovarian cancer: Which first-line treatment?	26
Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000–19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4	26
Clinical development of IDH1 inhibitors for cancer therapy	26
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers	26
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	25
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	25
Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data	25
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?	25
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias	25
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis	24
The use of immunotherapy in older patients with advanced non-small cell lung cancer	23
Prognostic factors in patients with oligometastatic breast cancer – A systematic review	23
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications	23
Organoid models in gynaecological oncology research	23
Novel targets for immune-checkpoint inhibition in cancer	22
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	22
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment	22
Beyond HER2: Targeting the ErbB receptor family in breast cancer	22
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC	21
A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research	21
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)	21
Targeting NaPi2b in ovarian cancer	21
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?	21
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)	20
Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis	20
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon	20
Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis	20
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	20
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences	19
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines	19
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts	19
Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?	19
Rethinking breast cancer follow-up based on individual risk and recurrence management	19
Checkpoint inhibitors in metastatic papillary renal cell carcinoma	19
Current management and future perspectives of penile cancer: An updated review	19
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis	19
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants	19
Toxicities following CAR-T therapy for hematological malignancies	19
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – A review	19
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer	18
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion–positive non-small cell lung cancers and future perspectives	18
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data	18
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage	18
De-escalation of axillary irradiation for early breast cancer – Has the time come?	18
The evolving landscape of antibody-drug conjugates in gynecologic cancers	18
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer	17
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review	17
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?	17
Systematic review of fetal and placental metastases among pregnant patients with cancer	17
Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges	17
Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery	17
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis	17
Advances in immunotherapy for MMR proficient colorectal cancer	17
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics	17
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment	17
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy	17
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies	16
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy	16
Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis	16
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge	16
Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers	16
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies	16
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists	16
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives	16
Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review	15
Basket trials: From tumour gnostic to tumour agnostic drug development	15
HER2 targeted therapy in colorectal cancer: New horizons	15
Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer	15
Current state of play for HPV-positive oropharyngeal cancers	15
The conundrum of breast cancer and microbiome - A comprehensive review of the current evidence	15
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?	15
Immunotherapy in advanced anal cancer: Is the beginning of a new era?	15
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies	15
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis	15
Germline TP53 pathogenic variants and breast cancer: A narrative review	15
The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 ×5 Gy) in rectal cancer - are we too eager for surgery?	15
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality	15
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news	15

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer	14
Treatment of venous thromboembolism in cancer patients: The dark side of the moon	14
Acquired resistance mechanisms to osimertinib: The constant battle	14
Immunotherapy-based combinations in metastatic NSCLC	14
Systematic review of the CUP trials characteristics and perspectives for next-generation studies	14
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis	14
Desmoplastic Small Round Cell Tumors: A review with focus on clinical management and therapeutic options	14
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of	13
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	13
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?	13
Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis	13
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario	13
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors	13
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review	12
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations	12
The microbiota and radiotherapy for head and neck cancer: What should clinical oncologists know?	12
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis	12
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	12
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review	12
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside	12
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	12
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification	12
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features	12
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis	11
Function and targeting of MALT1 paracaspase in cancer	11
Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours	11
Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review	11
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials	11
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision	11
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis	11
Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy	11
Association of immune checkpoint inhibitors with respiratory infections: A review	10
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence	10
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?	10
Strategies for improving detection of circulating tumor DNA using next generation sequencing	10
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice	10
Is DNA repair a potential target for effective therapies against malignant mesothelioma?	10
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review	10
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis	9
Low grade serous ovarian cancer – A rare disease with increasing therapeutic options	9
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis	9
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review	9
Drug dosing in cancer patients with decreased kidney function: A practical approach	9
The association between guideline adherence, age and overall survival among women with non-metastatic breast cancer: A systematic review	9
Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review	9
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer	9
Dietary influences on symptomatic and non-symptomatic toxicities during cancer treatment: A narrative review	9
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination	9
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review	9
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing	9
Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis	8
European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer	8
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee	8
A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead	8
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology	8
Uncertainties and controversies in axillary management of patients with breast cancer	8
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy	8
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives	8
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer	8
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer	8
A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors	8
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives	8
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II	8
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review	8
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis	8
Repositioning PARP inhibitors in the treatment of thoracic malignancies	8
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments	8
Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis	7
Neuroblastoma survivors at risk for developing subsequent neoplasms: A systematic review	7
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review	7
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies	7
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature	7
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	7
Pleural mesothelioma (PM) – The status of systemic therapy	7
Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review	7
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy	7
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know	7
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	7
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features	7
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?	7
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review	7
Uveal melanoma: In the era of new treatments	7
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action	7
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy	7
Identifying patient values impacting the decision whether to participate in early phase clinical cancer trials: A systematic review	7
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I	7